

ITL contract extended with bioMérieux

ITL Limited, the diversified healthcare company and owner of MyHealthTest, the provider of direct to consumer pathology testing, is pleased to announce a one year contract extension with bioMérieux (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries.

ITL has been a partner of bioMérieux for over three years for the supply of SampLok Sampling Kit (SSK) in the U.K. and over that time, the partnership has generated AUD ~\$4.5M in revenue for ITL. SSK is used in the global blood banking market to transfer platelet samples when performing bacterial detection testing.

bioMérieux has been a world leader in *in vitro* diagnostics for more than 50 years, and is present in over 150 countries through 42 subsidiaries and a large network of distributors.

The contract extension is in line with ITL's strategy to grow sales of SSK in existing and new markets around the globe. In 2016 ITL has already announced acceptance for approval of SSK by OneBlood, a large US blood bank, a contract extension with a second large US blood bank, the grant of the SSK patent in the US, as well as Taiwan FDA approval for the product.

Bill Mobbs, Executive Chairman commented "this contract extension with a world leader in the field of *in vitro* diagnostics is an excellent achievement by ITL BioMedical. With the continued partnership with bioMérieux, the recently granted patent in the US and the Taiwan FDA approval, SSK continues to show growth promise in new markets and with partners around the globe."

Bill Mobbs
Executive Chairman

ITL Limited ABN 16 088 212 088
Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.

Australian Securities Exchange

Code: ITD

Ordinary Shares

95,357,346

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer and Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Chief Financial Officer and Company Secretary
---------------	--

Phone: +61 3 8773 3050

Email: info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles	Walbrook IR
-------------	-------------

Phone: +61 426 277 760

Email: ben.knowles@walbrookir.com.au

About ITL BioMedical

ITL BioMedical is a division of ITL Limited. The division has a range of bacterial screening ancillaries as part of its wider portfolio of biological sampling and transfer kits. The division's products are distributed by industry leaders and partners around the world.

About bioMérieux

Pioneering Diagnostics

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms and preventing contamination in blood components, agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market

(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN: FR0010096479)

Corporate website: www.biomerieux.com

Industry website: www.biomerieux-industry.com